Replimune to Present at Two Upcoming Investor Conferences

Rhea-AI Summary

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company, announced its participation at two upcoming conferences. The company will host a fireside chat during the BMO Biopharma Spotlight Series Oncology Day on November 9, 2022, at 7:30 am EST. Additionally, Replimune will participate in the 13th Annual Jefferies Global Healthcare Conference on November 16, 2022, at 1:30 pm GMT.

Investors can access a live webcast of the Jefferies conference via Replimune's website.

WOBURN, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences:

BMO Biopharma Spotlight Series Oncology Day
Date: Wednesday, November 9, 2022
Fireside Chat Time: 7:30 am EST

13^th Annual Jefferies Global Healthcare Conference
Date: Wednesday, November 16, 2022
Fireside Chat Time: 1:30 pm GMT

A live webcast and replay of the fireside chat at the 13^th Annual Jefferies Global Healthcare Conference will also be available in the Investors section of Replimune’s website at www.replimune.com.

About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform has a unique dual local and systemic mechanism of action (MOA) consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment (TME) to ignite a strong and durable systemic response. This MOA is expected to be synergistic with most established and experimental cancer treatment modalities, and, with an attractive safety profile the RPx platform has the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.

Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com 

Media Inquiries
Lissette Steele
Verge Scientific Communications
202.930.4762 x 409
lsteele@vergescientific.com 

FAQ

What is the date and time of Replimune's fireside chat at the BMO Biopharma Spotlight Series Oncology Day?

Replimune's fireside chat at the BMO Biopharma Spotlight Series Oncology Day is scheduled for November 9, 2022, at 7:30 am EST.

When will Replimune present at the Jefferies Global Healthcare Conference?

Replimune will present at the 13th Annual Jefferies Global Healthcare Conference on November 16, 2022, at 1:30 pm GMT.

Where can I find the webcast of Replimune's presentation at the Jefferies conference?

The live webcast of Replimune's presentation at the Jefferies conference will be available on their website in the Investors section.

What is the focus of Replimune as a biotechnology company?

Replimune focuses on developing tumor-directed oncolytic immunotherapies to transform cancer treatment.

What is the stock symbol for Replimune?

The stock symbol for Replimune is REPL, traded on NASDAQ.